Emergent BioSolutions Inc.
EBS
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $304.9M
$5.91
▼ -0.51%
P/E
-1.74
Mkt Cap
$304.9M
52-Wk Range
$4.36–$14.06
52-Week Range
$4.36 - $14.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Exclusive government contracts and procurement relationships with U.S. Department of Defense and HHS
- Specialized expertise in CBRN medical countermeasures with high regulatory barriers to entry
- Established market leadership in critical vaccines (anthrax, smallpox) with limited competition
- Integrated CDMO capabilities enabling end-to-end product development and manufacturing
- Portfolio of FDA-approved products generating stable, recurring revenue streams
Bear Case
2 risks
- High volatility (beta 2.4). Larger-than-normal price swings expected.
- Premium valuation to Large Cap Pharma peers
Growth
Turning profitable
Increasing government spending on biodefense and pandemic preparedness initiatives
Value
Premium valuation to Large Cap Pharma peers
Momentum
Falling
-35.2% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EBS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
AUG 5, 2026
Reported EPS of $0.60 vs -$0.09 consensus (+805.9% surprise). Revenue of $234.3M vs $177.5M expected (+32.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+805.9%
Revenue trend · last 8Q
—
-30%
-26%
-45%
-21%
-24%
-30%
+66%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$293.8M
$194.7M
$222.2M
$140.9M
$231.1M
$148.7M
$156.1M
$234.3M
Margins · last 8Q
Gross
0.0%
Operating
-53.4%
Profit
-76.9%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Benchmark · Jun 2, 2026
vs Industry
How EBS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related